Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A

Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. Class A

SSZSE:301130
22.34
CNY
-0.64
(-2.79%)
-0.08EPS
2.18BMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.62
2.8
3.54
3.76
4.77
4.62
5.36
4.72
4.71
3.3
2.79
3.29
3.07
2.57
Basic EPS, GAAP
0.64
0.69
0.74
0.94
0.8
0.68
0.9
0.82
0.86
0.53
0.63
0.52
0.29
-0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
-0.22
0.58
0.87
0.83
0.62
0.17
-0.85
-1.04
-0.23
- -
Dividend per Share
0.68
0.35
0.16
0.3
0.19
0.2
0.3
0.4
- -
0.14
0.16
0.26
0.27
0.15
Book Value per Share
2.23
2.67
3.21
3.78
6.29
6.77
7.37
7.79
8.65
11.7
12.16
11.21
11.82
11.36
Tangible Book Value per Share
2.13
2.57
3.11
3.69
5.84
6.36
6.99
7.32
8.19
11.37
11.85
9.6
10.16
9.18
Basic Weighted Avg Shares
44
54
54
54
57
61
61
61
61
77
81
78
76
76
Sales/Revenue/Turnover
116
151
193
204
274
280
325
286
286
255
225
256
235
195
Operating Margin (%)
26.59
24.97
21.08
21.9
19.28
16.81
19.2
19.33
19.67
15.63
16.69
15.86
7.3
-6.52
Depreciation Expense
- -
- -
- -
- -
14
18
21
20
19
18
19
23
35
- -
Net Income, GAAP
28
37
40
51
46
41
55
50
52
41
51
40
22
-5
Effective Tax Rate (%)
16
15.57
16.02
15.36
15.78
14.43
15.21
15.59
12.14
19.25
13.39
13.43
5.23
- -
Profit Margin (%)
24.42
24.62
20.92
25.01
16.68
14.76
16.81
17.37
18.21
15.94
22.4
15.71
9.33
-2.44
Working Capital
50
77
71
42
120
148
195
229
280
665
580
294
254
238
LT Debt
- -
- -
4
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
28
Total Equity
135
162
194
229
381
410
447
472
524
945
983
941
935
898
Return on Invested Capital (%)
- -
18.58
18.04
21.17
14.69
10.55
13.2
11.03
10.52
5.68
4.98
4.14
2.02
- -
Return on Capital (%)
- -
23.3
21.81
23.66
14.88
10.46
12.75
10.83
10.44
5.54
5.24
4.17
2.56
- -
Return on Common Equity (%)
- -
25.08
22.63
24.05
14.96
10.46
12.75
10.83
10.44
5.54
5.24
4.26
2.42
-0.54

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
12
12
13
LT Borrowings
28
28
28
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
76
76
Market Capitalization
2,382
1,834
2,181

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
330
334
334
Cash, Cash Equivalents & STI
222
224
230
Accounts Receivable, Net
34
32
27
Inventories
32
32
26
Total Current Liabilities
70
100
96
Payables & Accruals
- -
- -
- -
ST Debt
12
12
13
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.68%
18.08%
-0.68%
Free Cash Flow
- -
-157.54%
-78.4%
Net Income, GAAP
-2.93%
-11.8%
-45.62%
Sales/Revenue/Turnover
2.93%
-3.45%
-8.41%
Total Cash Common Dividend
- -
- -
1.5%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
67
62
64
64
256
2025
52
76
- -
46
235
2026
56
46
48
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.14
0.13
0.08
0.52
2025
0.11
0.22
- -
-0.15
0.29
2026
0.12
- -
-0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.26
2025
- -
0.26
- -
- -
0.27
2026
- -
0.15
- -
- -
- -

Company Description

CEO
Jun Zhang
Full Time Employees
313
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.777, West Point Street Changchun JI China 132300
IPO Date
Feb 23, 2022
Business
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations primarily in China. The company offers anti-anemia drugs such as compound ferrous sulfate folic acid tablets (Yiyuansheng) and ferrous sulfate; antipsychotic and antidepressant medications including risperidone tablets, escitalopram oxalate tablets, and rexianthin capsules; circulatory system drugs; tumor treatments; and raw materials like ferrous fumarate and revanillin, provided mainly in tablet and capsule forms. Founded in 1990 and headquartered in Panshi, Jilin Province, China, it operates with a focus on domestic markets while advancing a global strategy, employing around 320 people and listing on the Shenzhen Stock Exchange (301130.SZ). Recent developments include the approval of levofloxacin eye drops, enhancing its product portfolio in ophthalmic treatments, alongside ongoing shareholding reductions by major shareholders such as Hengqin Dingdian and affiliates in 2025, and modest net profit growth of 2.02% in the first half of 2025 to RMB 24.9446 million.